Abstract
Since the first case of acquired immunodeficiency syndrome (AIDS) was reported in 1981, AIDS has always been a global health threat and the leading cause of deaths due to the rapid emergence of drug-resistance and unwanted metabolic side effects. Every day in 2007 an estimated 6850 people were newly infected with human immunodeficiency virus (HIV). Over the past 28 years the rapid worldwide spread of AIDS has prompted an intense research effort to discover compounds that could effectively inhibit HIV. The development of new, selective and safe inhibitors for the treatment of HIV, therefore, still remains a high priority for medical research. To the best of our knowledge, the indole derivatives have been considered as one class of promising HIV-1 inhibitors, such as delavirdine approved by the Food and Drug Administration (FDA) in 1997 for use in combination with other antiretrovirals in adults with HIV infection. In this review we focus on the synthesis and anti-HIV-1 activity of indole derivatives, in the meantime, the structure – activity relationship (SAR) for some derivatives are also surveyed. It will pave the way for the design of indole derivatives as anti- HIV-1 drugs in the future.
Keywords: Indole, synthesis, acquired immunodeficiency syndrome, human immunodeficiency virus, inhibitor, structure, –, activity relationship
Current Pharmaceutical Design
Title: Developments of Indoles as Anti-HIV-1 Inhibitors
Volume: 15 Issue: 18
Author(s): Hui Xu and Min Lv
Affiliation:
Keywords: Indole, synthesis, acquired immunodeficiency syndrome, human immunodeficiency virus, inhibitor, structure, –, activity relationship
Abstract: Since the first case of acquired immunodeficiency syndrome (AIDS) was reported in 1981, AIDS has always been a global health threat and the leading cause of deaths due to the rapid emergence of drug-resistance and unwanted metabolic side effects. Every day in 2007 an estimated 6850 people were newly infected with human immunodeficiency virus (HIV). Over the past 28 years the rapid worldwide spread of AIDS has prompted an intense research effort to discover compounds that could effectively inhibit HIV. The development of new, selective and safe inhibitors for the treatment of HIV, therefore, still remains a high priority for medical research. To the best of our knowledge, the indole derivatives have been considered as one class of promising HIV-1 inhibitors, such as delavirdine approved by the Food and Drug Administration (FDA) in 1997 for use in combination with other antiretrovirals in adults with HIV infection. In this review we focus on the synthesis and anti-HIV-1 activity of indole derivatives, in the meantime, the structure – activity relationship (SAR) for some derivatives are also surveyed. It will pave the way for the design of indole derivatives as anti- HIV-1 drugs in the future.
Export Options
About this article
Cite this article as:
Xu Hui and Lv Min, Developments of Indoles as Anti-HIV-1 Inhibitors, Current Pharmaceutical Design 2009; 15 (18) . https://dx.doi.org/10.2174/138161209788489168
DOI https://dx.doi.org/10.2174/138161209788489168 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
2', 4'-dihydroxy-3, 4-methylenedioxychalcone Activate Mitochondrial Apoptosis of Ehrlich Ascites Carcinoma Cells
Current Drug Therapy Challenges and Opportunities of Nanotechnological based Approach for the Treatment of Tuberculosis
Current Pharmaceutical Design Old Drugs and New Targets as an Outlook for the Treatment of Tuberculosis
Current Medicinal Chemistry Mouse Models of Autoimmune Uveitis
Current Pharmaceutical Design T Cell Cytokine Production in Childhood Asthma
Current Respiratory Medicine Reviews Prospects for Clinical Introduction of Nitroimidazole Antibiotics for the Treatment of Tuberculosis
Current Pharmaceutical Design Effects of Mefepronic Acid (2-Phenoxy-2-Methyl Propionic Acid) on Hepatic Metabolism and Reproductive Parameters in Postpartum Dairy Cows
Endocrine, Metabolic & Immune Disorders - Drug Targets Identifying Multiple-target Ligands via Computational Chemogenomics Approaches
Current Topics in Medicinal Chemistry <i>Larrea tridentata</i> and its Biological Activities
Current Topics in Medicinal Chemistry Proteomic analysis of a <i>hom</i>-disrupted, cephamycin C overproducing <i>Streptomyces clavuligerus</i>
Protein & Peptide Letters Antibacterial Activity and Structure-Activity Relationship Studies of 4- aryl/alkyl-1-(diphenylacetyl)thiosemicarbazides
Letters in Drug Design & Discovery The Use of Affinity Tags to Overcome Obstacles in Recombinant Protein Expression and Purification
Protein & Peptide Letters Chemistry and Biology of Indoles and Indazoles: A Mini-Review
Mini-Reviews in Medicinal Chemistry Evaluation of Stationary Phases Made by Hydrosilation of Alkynes on Silica Hydride
Current Chromatography Screening of Antioxidant, Antimicrobial Activities and Chemical Contents of Edible Mushrooms Wildly Grown in the Black Sea Region of Turkey
Combinatorial Chemistry & High Throughput Screening A Novel Advanced Laboratory Diagnosis to Guide Tuberculosis Drug Therapy.
Recent Patents on Anti-Infective Drug Discovery The Long Pentraxin PTX3, a Soluble Pattern Recognition Receptor Involved in Innate Immunity,Inflammation and Female Fertility
Current Immunology Reviews (Discontinued) Dysregulation of RNA Mediated Gene Expression in Motor Neuron Diseases
CNS & Neurological Disorders - Drug Targets Designed Multiple Ligands: Basic Research vs Clinical Outcomes
Current Medicinal Chemistry Targeting Pattern Recognition Receptors (PRRs) in Nano- Adjuvants: Current Perspectives
Current Bionanotechnology (Discontinued)